explore -WSS

explore

author：fashion 2025-09-27 19:50:12 - browse：11

LONDON — AstraZeneca said Tuesday it would acquire Fusion Pharmaceuticals in a deal worth more than $2 billion, picking up a company focused on the booming area of targeted radiation therapies for cancer.

AstraZeneca will pay $2 billion in cash upfront for Fusion, a price that at $21 a share is nearly double Fusion’s closing share price on Monday. If certain regulatory milestones are met, AstraZeneca will pay another $3 a share, or roughly $400 million.

Fusion specializes in developing radiopharmaceuticals, also known as radioconjugates or radioligands, which deliver radiation directly to tumors, guided by particular markers on cancer cells. The aim is not only to minimize the risk of damaging surrounding, healthy tissue, but also to reach tumors that traditional radiation can’t.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Albert Bourla of Pfizer: worst biopharma CEO of 2023

hotspot

focus

WSS

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

SNAP should offer more nutrition education

FDA needs staff influx to meet gene therapy needs, Marks says

Carvykti CAR

The woman behind the Dana Farber

Americans' trust in science, scientist continues decline: Report

hotspot

explore

focus

Tori Bowie and the unacceptable rates of Black maternal death

Grail spinoff by Illumina should end disastrous merger attempt

23andMe had bad news about my health. I wish a person had delivered it

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

State Dept. review finds Biden bears some blame for Afghanistan failures

Why health care costs have stayed mostly flat since 2010

The cancer drug shortage isn’t new — and neither are the solutions

Chemotherapy shortages won’t get better under Biden’s latest plan

Drug repurposing or repositioning? The language matters

How to keep neuroscience’s past racism from being its future

knowledge

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

Can sheer will power keep patients alive in their dying hours?

Pharma patents targeted by Biden in move to slash drug prices

Virtual care provider acquires bankrupt Pear's prescription apps

Readout Newsletter: The latest on Moderna, Apellis, and Merck

Why sickle cell disease is getting the first CRISPR treatment

leisure time

hotspot

focus

leisure time